Zydus Cadila has received the final approval from the USFDA to market Desvenlafaxine Extended-Release Tablets, 50 mg and 100 mg. The drug is used to treat major depression and will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad. The group now has more than 160 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.